辅助中成药治疗对预防食管胃底静脉曲张再出血的回顾性队列研究
该回顾性队列纳入555例肝硬化静脉曲张出血恢复期患者,按是否辅助使用中成药(≥28 cDDDs)分为中成药组139例和非中成药组416例,随访至少12个月。多因素分析显示中成药治疗为再出血独立保护因素(AHR=0.657),1:2倾向性评分匹配后中成药组1年再出血率44.6%低于非中成药组58.3%(P=0.002),且再出血中位时间延长(113.5 vs 93.0天)。
要点
- 辅助中成药与肝硬化静脉曲张再出血风险降低独立相关(AHR=0.657)。
- 中成药累积剂量越高,再出血风险降低越明显(>180 cDDDs时AHR=0.105)。
核心结论
- 在标准治疗基础上辅助使用中成药可显著降低静脉曲张再出血发生率并延迟再出血时间。
研究设计与样本
- 回顾性队列研究,连续纳入555例肝硬化静脉曲张出血恢复期患者,按是否辅助使用中成药(≥28 cDDDs为暴露)分组,中成药组139例、非中成药组416例,随访至少12个月,采用1:2倾向性评分匹配减少偏倚。
主要发现
- 多因素分析显示中成药治疗为静脉曲张再出血的独立保护因素(AHR=0.657,95%CI 0.497-0.868,P=0.003)。
- 1:2倾向性评分匹配后,中成药组1年再出血率为44.6%,非中成药组为58.3%,降低23.5%(modified log-rank检验,P=0.002)。
- 中成药累积剂量28-90、91-180、>180 cDDDs对应的再出血AHR分别为0.928、0.553、0.105。
- 中成药组再出血中位间隔时间为113.5天,非中成药组为93.0天(P=0.008)。
关键数值与推荐
- 中成药暴露定义为累积定义日剂量(cDDDs)≥28。
- 研究终点为临床显著食管胃底静脉曲张再出血。
临床怎么用
- 对于肝硬化静脉曲张出血恢复期患者,在标准治疗基础上可考虑辅助使用中成药以降低再出血风险,且累积剂量较高者可能获益更明显。
局限性
- 本研究为回顾性队列研究,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether adjuvant Chinese patent medicines (CPMs) to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients. METHODS: This study retrospectively collected 555 consecutive patients who recovered from variceal bleeding. A population-based cohort study was established depending on if adjuvant CPMs were administered to prevent rebleeding. A total of 139 patients who had taken ⩾28 cumulative defined daily doses (cDDDs) of CPMs were included in the CPMs cohort, and 416 patients who used <28 cDDDs of CPMs were enrolled in the non-CPMs cohort. On evaluation of rebleeding incidence, 1:2 propensity score matched was used to estimate for reducing bias. Patients were followed for at least 12 months. The end-point of this study was clinically significant esophagogastric variceal rebleeding. RESULTS: Following multivariate analysis, CPMs therapy was an independent factor for variceal rebleeding [adjusted hazard ratio (AHR)=0.657; 95% confidence interval=0.497-0.868; P=0.003]. After the 1:2 propensity score matching, a significant reduction (23.5%) in the incidence of variceal rebleeding in patients was observed, from 58.3% in the non-CPMs cohort to 44.6% in the CPMs cohort (modified log-rank test, P=0.002) within a year. The AHRs for rebleeding were 0.928, 0.553, and 0.105, for 28-90 cDDDs, 91-180 cDDDs, and >180 cDDDs of CPMs, respectively. The median rebleeding interval in the CPMs cohort was significantly larger compared with the non-CPMs cohort (113.5 vs. 93.0 days; P=0.008). CONCLUSION: Adjuvant CPMs to standard therapy can significantly reduce the incidence of variceal rebleeding and delay the time to rebleeding.
引用
- Zhang Q, Li YX, Liu Y, et al. Effects of Adjuvant Chinese Patent Medicine Therapy on Prevention of Variceal Rebleeding: A Retrospective Cohort Study. Chin J Integr Med. 2021. PMID: 32876859. doi:10.1007/s11655-020-3272-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。